{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T21:53:41Z","timestamp":1766181221374,"version":"3.44.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Bayer Consumer Health AG"},{"name":"Pharmaceuticals"},{"name":"Bayer Consumer Health AG"},{"name":"Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.survophthal.2019.02.008","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T06:46:23Z","timestamp":1550817983000},"page":"707-719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["The use of real-world evidence for evaluating anti\u2013vascular endothelial growth factor treatment of neovascular age-related macular degeneration"],"prefix":"10.1016","volume":"64","author":[{"given":"James","family":"Talks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Daien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Finger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bora","family":"Eldem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Augusto","family":"Cardillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tien Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Korobelnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.survophthal.2019.02.008_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ophtha.2012.10.006","article-title":"Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration","volume":"120","author":"Abedi","year":"2013","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.008_bib2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/sj.eye.6703053","article-title":"Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss","volume":"23","author":"Arias","year":"2009","journal-title":"Eye (Lond)"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.008_bib3","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.ophtha.2015.02.009","article-title":"Two-year outcomes of \u201ctreat and extend\u201d intravitreal therapy for neovascular age-related macular degeneration","volume":"122","author":"Arnold","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.008_bib5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.survophthal.2019.02.008_bib6","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1136\/bjophthalmol-2015-308090","article-title":"Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration","volume":"100","author":"Barthelmes","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2019.02.008_bib7","doi-asserted-by":"crossref","first-page":"e7885","DOI":"10.1136\/bmj.e7885","article-title":"Comorbidity in patients with branch retinal vein occlusion: case-control study","volume":"345","author":"Bertelsen","year":"2012","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.survophthal.2019.02.008_bib8","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/j.ophtha.2013.07.053","article-title":"Prediction of age-related macular degeneration in the general population: the Three Continent AMD Consortium","volume":"120","author":"Buitendijk","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2019.02.008_bib9","doi-asserted-by":"crossref","first-page":"e4203","DOI":"10.1136\/bmj.e4203","article-title":"Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study","volume":"345","author":"Campbell","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.survophthal.2019.02.008_bib10","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1186\/1471-2458-13-670","article-title":"High prevalence of diagnosis of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden \u2013 a challenge for public health","volume":"13","author":"Carlsson","year":"2013","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.008_bib12","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ajo.2006.10.004","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study","volume":"143","author":"Chen","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2019.02.008_bib13","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.ophtha.2017.03.056","article-title":"Six-year incidence of age-related macular degeneration in Asian Malays: the Singapore Malay Eye Study","volume":"124","author":"Cheung","year":"2017","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.008_bib14","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/eye.2015.217","article-title":"Ranibizumab for the treatment of wet AMD: a summary of real-world studies","volume":"30","author":"Chong","year":"2016","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.008_bib15","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ophtha.2016.11.016","article-title":"Type 2 diabetes genetic variants and risk of diabetic retinopathy","volume":"124","author":"Chong","year":"2017","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.008_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000456721","article-title":"French Medical-Administrative Database for Epidemiology and Safety in Ophthalmology (EPISAFE): the EPISAFE Collaboration Program in Cataract Surgery","volume":"58","author":"Daien","year":"2017","journal-title":"Ophthalmic Res"},{"issue":"8","key":"10.1016\/j.survophthal.2019.02.008_bib18","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.ophtha.2015.04.017","article-title":"Incidence and characteristics of cataract surgery in France from 2009 to 2012: a national population study","volume":"122","author":"Daien","year":"2015","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.survophthal.2019.02.008_bib19","doi-asserted-by":"crossref","first-page":"e005094","DOI":"10.1136\/bmjopen-2014-005094","article-title":"Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial","volume":"4","author":"Dakin","year":"2014","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.008_bib20","first-page":"467","article-title":"GRACE principles: recognizing high-quality observational studies of comparative effectiveness","volume":"16","author":"Dreyer","year":"2010","journal-title":"Am J Manag Care"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.008_bib21","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.ophtha.2016.02.015","article-title":"High variation of intravitreal injection rates and medicare anti-vascular endothelial growth factor payments per injection in the United States","volume":"123","author":"Erie","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2019.02.008_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ajo.2016.06.019","article-title":"Safety assessment and power analyses in published anti-vascular endothelial growth factor randomized controlled trials","volume":"169","author":"Esen","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.008_bib23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archopht.1996.01100130537006","article-title":"Risk factors for central retinal vein occlusion","volume":"114","year":"1996","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.008_bib24","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ophtha.2013.12.032","article-title":"The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration","volume":"121","author":"Finger","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.008_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2013.03.009","article-title":"Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration","volume":"59","author":"Finger","year":"2014","journal-title":"Surv Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.008_bib27","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.ahj.2010.08.040","volume":"160","author":"Fr\u00f6bert","year":"2010","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.008_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jamaophthalmol.2014.4252","article-title":"Severity of age-related macular degeneration in 1 eye and the incidence and progression of age-related macular degeneration in the fellow eye: the Beaver Dam Eye Study","volume":"133","author":"Gangnon","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.008_bib29","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","article-title":"Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report","volume":"10","author":"Garrison","year":"2007","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.survophthal.2019.02.008_bib30","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","article-title":"Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.008_bib31","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.ophtha.2016.05.054","volume":"124","author":"Gillies","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2019.02.008_bib32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2288-3-28","article-title":"Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity","volume":"3","author":"Godwin","year":"2003","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.008_bib33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2217\/cer.12.23","article-title":"Building useful evidence: changing the clinical research paradigm to account for comparative effectiveness research","volume":"1","author":"Greenfield","year":"2012","journal-title":"J\u00a0Comp Eff Res"},{"issue":"9300","key":"10.1016\/j.survophthal.2019.02.008_bib34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(02)07283-5","article-title":"An overview of clinical research: the lay of the land","volume":"359","author":"Grimes","year":"2002","journal-title":"Lancet"},{"issue":"9302","key":"10.1016\/j.survophthal.2019.02.008_bib35","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(02)07451-2","article-title":"Bias and causal associations in observational research","volume":"359","author":"Grimes","year":"2002","journal-title":"Lancet"},{"issue":"9301","key":"10.1016\/j.survophthal.2019.02.008_bib36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(02)07373-7","article-title":"Descriptive studies: what they can and cannot do","volume":"359","author":"Grimes","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.008_bib37","first-page":"120593","article-title":"Comparison of AMD Treatments Trials Research Group pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT)","author":"Hagstrom","year":"2013","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.008_bib38","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamaophthalmol.2014.109","article-title":"VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT)","volume":"132","author":"Hagstrom","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"16","key":"10.1016\/j.survophthal.2019.02.008_bib39","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/CIRCULATIONAHA.107.721357","article-title":"Evaluating the evidence: is there a rigid hierarchy?","volume":"118","author":"Ho","year":"2008","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.survophthal.2019.02.008_bib40","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/bjophthalmol-2013-303232","article-title":"Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme","volume":"97","author":"Holz","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2019.02.008_bib41","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/eye.2016.90","article-title":"Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study","volume":"30","author":"Holz","year":"2016","journal-title":"Eye (Lond)"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.008_bib42","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s10384-016-0492-7","article-title":"One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy","volume":"61","author":"Hosokawa","year":"2017","journal-title":"Jpn J Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2019.02.008_bib43","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/bjophthalmol-2014-305275","article-title":"Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy","volume":"99","author":"Hosokawa","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2019.02.008_bib44","unstructured":"Iida T, Lee WK, Chen S-J, et\u00a0al., editors. Efficacy and safety of intravitreal aflibercept in polypoidal choroidal vasculopathy: the PLANET study. 10th Congress of the Asia-Pacific Vitreo-retina Society (APVRS); December 8\u201310, 2016, Bangkok, Thailand."},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.008_bib45","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00417-014-2707-2","article-title":"Short-term efficacy of intravitreal aflibercept for patients with treatment-na\u00efve polypoidal choroidal vasculopathy","volume":"253","author":"Ijiri","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2019.02.008_bib47","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1097\/IAE.0000000000000229","article-title":"Short-term efficacy of intravitreal aflibercept in treatment-naive patients with polypoidal choroidal vasculopathy","volume":"34","author":"Inoue","year":"2014","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.008_bib49","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrcardio.2015.33","article-title":"Registry-based randomized clinical trials\u2014a new clinical trial paradigm","volume":"12","author":"James","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"10.1016\/j.survophthal.2019.02.008_bib50","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/bjophthalmol-2016-309729","article-title":"Five-year progression of unilateral age-related macular degeneration to bilateral involvement: the Three Continent AMD Consortium report","volume":"101","author":"Joachim","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2019.02.008_bib51","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.ophtha.2015.08.002","article-title":"The incidence and progression of age-related macular degeneration over 15 years: the Blue Mountains Eye Study","volume":"122","author":"Joachim","year":"2015","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.008_bib52","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s12325-017-0483-1","article-title":"A\u00a0retrospective study of ranibizumab treatment regimens for neovascular age-related macular degeneration (nAMD) in Australia and the United Kingdom","volume":"34","author":"Johnston","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.survophthal.2019.02.008_bib53","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13063-016-1158-y","article-title":"Use of PRECIS ratings in the National Institutes of Health (NIH) Health Care Systems Research Collaboratory","volume":"17","author":"Johnson","year":"2016","journal-title":"Trials"},{"key":"10.1016\/j.survophthal.2019.02.008_bib54","doi-asserted-by":"crossref","first-page":"e2014008","DOI":"10.4178\/epih\/e2014008","article-title":"A\u00a0guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples","volume":"36","author":"Kim","year":"2014","journal-title":"Epidemiol Health"},{"issue":"8","key":"10.1016\/j.survophthal.2019.02.008_bib55","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.survophthal.2019.02.008_bib56","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ajo.2006.06.015","article-title":"Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study","volume":"142","author":"Klein","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2019.02.008_bib57","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1136\/bjophthalmol-2014-306432","article-title":"Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study","volume":"99","author":"Koizumi","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.008_bib58","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ajo.2012.06.031","article-title":"Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment","volume":"155","author":"Kr\u00fcger Falk","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.008_bib59","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A\u00a0variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"17","key":"10.1016\/j.survophthal.2019.02.008_bib60","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMp1310102","article-title":"The randomized registry trial \u2014 the next disruptive technology in clinical research?","volume":"369","author":"Lauer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.survophthal.2019.02.008_bib61","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/bjophthalmol-2014-306229","article-title":"UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6\/12","volume":"99","author":"Lee","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2019.02.008_bib62","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/eye.2016.149","article-title":"The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care","volume":"30","author":"Liew","year":"2016","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.1016\/j.survophthal.2019.02.008_bib63","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ajo.2011.09.013","article-title":"Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration","volume":"153","author":"Lim","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2019.02.008_bib64","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/eye.2012.199","article-title":"Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes","volume":"26","author":"Lyall","year":"2012","journal-title":"Eye (Lond)"},{"issue":"8","key":"10.1016\/j.survophthal.2019.02.008_bib65","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.008_bib66","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/2229-516X.157148","article-title":"Real world data: additional source for making clinical decisions","volume":"5","author":"Mahajan","year":"2015","journal-title":"Int J Appl Basic Med Res"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.008_bib67","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.survophthal.2018.02.004","article-title":"Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration","volume":"63","author":"Mantel","year":"2018","journal-title":"Surv Ophthalmol"},{"author":"Medisoft","key":"10.1016\/j.survophthal.2019.02.008_bib68"},{"key":"10.1016\/j.survophthal.2019.02.008_bib69","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","article-title":"Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors","volume":"65","author":"Mehta","year":"2018","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"10.1016\/j.survophthal.2019.02.008_bib70","doi-asserted-by":"crossref","first-page":"e42014","DOI":"10.1371\/journal.pone.0042014","article-title":"Impact of loading phase, initial response and CFH genotype on the long-term outcome of treatment for neovascular age-related macular degeneration","volume":"7","author":"Menghini","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.survophthal.2019.02.008_bib71","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S0161-6420(96)30449-1","article-title":"Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study","volume":"103","author":"Mitchell","year":"1996","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.008_bib72","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00417-010-1520-9","article-title":"Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity","volume":"249","author":"Muether","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.008_bib74","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ajo.2014.12.005","article-title":"Incidence of myocardial infarction, stroke, and death in patients with age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor therapy","volume":"159","author":"Ng","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.008_bib75","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ajo.2015.01.018","article-title":"One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome","volume":"159","author":"Oishi","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"Suppl 1","key":"10.1016\/j.survophthal.2019.02.008_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00347-016-0265-1","article-title":"The IRIS\u00ae Registry: purpose and perspectives","volume":"114","author":"Parke","year":"2017","journal-title":"Ophthalmologe"},{"issue":"9","key":"10.1016\/j.survophthal.2019.02.008_bib77","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamaophthalmol.2016.2166","article-title":"Assessment of the accuracy of using ICD-9 codes to identify uveitis, herpes zoster ophthalmicus, scleritis, and episcleritis","volume":"134","author":"Pimentel","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2019.02.008_bib78","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1136\/bjophthalmol-2012-302167","article-title":"Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration","volume":"96","author":"Pushpoth","year":"2012","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2019.02.008_bib79","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.survophthal.2019.02.008_bib80","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/eye.2012.61","article-title":"Visual impairment certification secondary to ARMD in Leeds, 2005\u20132010: is the incidence falling?","volume":"26","author":"Rostron","year":"2012","journal-title":"Eye (Lond)"},{"issue":"9453","key":"10.1016\/j.survophthal.2019.02.008_bib81","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cTo whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.008_bib83","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s10384-016-0478-5","article-title":"Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration","volume":"61","author":"Saito","year":"2017","journal-title":"Jpn J Ophthalmol"},{"issue":"9304","key":"10.1016\/j.survophthal.2019.02.008_bib84","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(02)07605-5","article-title":"Case-control studies: research in reverse","volume":"359","author":"Schulz","year":"2002","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.survophthal.2019.02.008_bib85","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence \u2014 what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.survophthal.2019.02.008_bib86","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1038\/ctg.2013.13","article-title":"A\u00a0primer on effectiveness and efficacy trials","volume":"5","author":"Singal","year":"2014","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.008_bib87","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ajo.2010.03.008","article-title":"Cohort studies: design and pitfalls","volume":"150","author":"Soh","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2019.02.008_bib88","doi-asserted-by":"crossref","first-page":"e113843","DOI":"10.1371\/journal.pone.0113843","article-title":"A\u00a0multi-center, cross-sectional study on the burden of infectious keratitis in China","volume":"9","author":"Song","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.survophthal.2019.02.008_bib89","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1161\/CIRCULATIONAHA.105.594945","article-title":"Design of randomized controlled trials","volume":"115","author":"Stanley","year":"2007","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.survophthal.2019.02.008_bib90","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/eye.2017.86","article-title":"Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration","volume":"31","author":"Talks","year":"2017","journal-title":"Eye (Lond)"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.008_bib91","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ophtha.2015.09.039","article-title":"First-year visual acuity outcomes of providing aflibercept according to the VIEW study protocol for age-related macular degeneration","volume":"123","author":"Talks","year":"2016","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.008_bib92","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jclinepi.2008.12.011","article-title":"A\u00a0pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers","volume":"62","author":"Thorpe","year":"2009","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.survophthal.2019.02.008_bib93","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1745-6215-10-37","article-title":"Making trials matter: pragmatic and explanatory trials and the problem of applicability","volume":"10","author":"Treweek","year":"2009","journal-title":"Trials"},{"issue":"9","key":"10.1016\/j.survophthal.2019.02.008_bib94","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1097\/IAE.0000000000000173","article-title":"Reasons for discontinuation of intravitreal vascular endothelial growth factor inhibitors in neovascular age-related macular degeneration","volume":"34","author":"Vaze","year":"2014","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.008_bib95","first-page":"CD007419","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis","author":"Virgili","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.008_bib98","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ophtha.2006.07.017","article-title":"Ten-year incidence and progression of age-related maculopathy: the Blue Mountains Eye Study","volume":"114","author":"Wang","year":"2007","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.survophthal.2019.02.008_bib99","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.ophtha.2015.05.024","article-title":"One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy","volume":"122","author":"Yamamoto","year":"2015","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.survophthal.2019.02.008_bib100","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.ophtha.2010.12.030","article-title":"Prevalence of age-related macular degeneration in a rural Chinese population: the Handan Eye Study","volume":"118","author":"Yang","year":"2011","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.survophthal.2019.02.008_bib101","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/j.ophtha.2012.06.043","article-title":"Five-year incidence of age-related macular degeneration: the Beijing Eye Study","volume":"119","author":"You","year":"2012","journal-title":"Ophthalmology"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625717303375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625717303375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:49:27Z","timestamp":1758541767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625717303375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0039625717303375"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2019.02.008","relation":{},"ISSN":["0039-6257"],"issn-type":[{"type":"print","value":"0039-6257"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of real-world evidence for evaluating anti\u2013vascular endothelial growth factor treatment of neovascular age-related macular degeneration","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2019.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}